Aspirin to prevent heart attack or stroke
- 1 January 1994
- journal article
- review article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 32 (1) , 1-3
- https://doi.org/10.1136/dtb.1994.3211
Abstract
Each year in the United Kingdom about 250,000 people die from acute myocardial infarction, other ischaemic heart disease or stroke. Many will already have evidence of established vascular disease that predisposes to such an event--such as angina, peripheral vascular disease, atrial fibrillation, transient ischaemic attacks or a previous myocardial infarction or stroke. Others will have risk factors such as hypertension, diabetes mellitus or hyperlipidaemia, but the stroke or heart attack is the first evidence of established vascular disease. Aspirin was first discovered to have antiplatelet properties 30 years ago and since then many randomised clinical trials have sought to determine whether it (or other antiplatelet agents) can protect patients from heart attack or stroke. In this article we review the evidence and update our earlier conclusions on stroke, myocardial infarction, and unstable angina, arguing that aspirin should be widely used to reduce cardiovascular morbidity and mortality in certain high-risk patients.Keywords
This publication has 10 references indexed in Scilit:
- Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patientsBMJ, 1994
- Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapyBMJ, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic StrokeNew England Journal of Medicine, 1991
- The management of unstable anginaDrug and Therapeutics Bulletin, 1990
- Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and backTrends in Pharmacological Sciences, 1989
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- Aspirin and myocardial infarctionDrug and Therapeutics Bulletin, 1987
- Management of stroke: 12 hours to 2 monthsDrug and Therapeutics Bulletin, 1985